An announcement from Evotec AG ( (EVO) ) is now available.

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the ...

Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...

Adimab's latest partner program to receive approval is GSK's Exdensur (depemokimab), approved in the US for the treatment of severe asthma with an eosinophilic phenotype and in the UK and Japan for ...

A new shot is helping protect more babies from RSV. A Dayton doctor said it is already dramatically reducing hospitalizations ...

Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics Leading candidate ...

As of Friday, January 09, Coherus Oncology, Inc.’s CHRS share price has surged by 6.86%, which has investors questioning if ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the program Supports the feasibility of intravenous and subcutaneous dosing regimens in ...

As people with α-gal syndrome seek to boost awareness, researchers are looking to harness the molecule for new therapies ...

The federal government is no longer broadly recommending several vaccines as part of the Trump administration and Health ...

A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...